Alexion to present seven abstracts, including four oral presentations, from its leading rare neurology portfolio at EAN 2025: Cambridge, UK Monday, June 23, 2025, 13:00 Hrs [IST] ...

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company listed on the Nasdaq Composite Russell 1000 ...

Approval in Myasthenia gravis in key markets could eventually ... label study which found benefits for patients with anti-AchR antibody-positive gMG who had previously failed immunosuppressive ...

The FDA has become the first global regulator to approve UCB’s Rystiggo, a treatment for generalised myasthenia gravis that the ... both anti-AChR and anti-MuSK antibody-positive gMG based ...